Subscribe To
Gsk cancer immunotherapy receives backing from key ema committee
GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recommended for approval by a key committee at the E...
October 16, 2023, 4:02 am
Gilead sciences stock is cheap, with broad pipeline
Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its t...
October 15, 2023, 9:45 pm
Carmot therapeutics highlights clinical data from its pipeline of treatments for obesity and diabetes at obesityweek®
– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week ...
October 15, 2023, 4:00 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm